Pfizer (PFE) News Today

Pfizer Inc. (PFE) shares ticked up mid‐day as investors absorbed a mix of positive catalysts—ranging from FDA approvals and bullish analyst comparisons—to cautionary signals from elevated put‐option activity and workforce reductions.

• Positive Sentiment: U.S. FDA granted approval for the supplemental biologics license (sBLA) of COMIRNATY® LP.8.1 for adults 65+ and high‐risk individuals ages 5–64, broadening the vaccine’s commercial potential. Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval…
• Positive Sentiment: Analyst note from Zacks highlights Pfizer’s cost-cutting measures, pipeline of new products and cheaper valuation versus Eli Lilly, positioning PFE as the better pharma pick. LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?
• Positive Sentiment: Seeking Alpha highlights an attractive dividend growth valuation screen, ranking Pfizer among twenty high-quality dividend growers, which may attract income-focused investors. Pfizer: Finally Some Fortune, Plus Twenty High-Quality Dividend Growth Valuations
• Positive Sentiment: Benzinga reports “smart money” institutional investors are increasing their PFE options bets, signaling confidence in an upside move. Smart Money Is Betting Big In PFE Options
• Positive Sentiment: A Sohu piece argues Pfizer is entering a “new era beyond COVID revenue,” driven by diverse therapeutic launches and longer-term growth prospects. Pfizer: A New Era Beyond COVID Revenue
• Positive Sentiment: Another Sohu analysis highlights Pfizer “emerging stronger” post-COVID revenue decline, pointing to robust R&D and margin recovery. Pfizer: Emerging Stronger Post-COVID Revenue Decline
• Positive Sentiment: A separate Sohu article underscores Pfizer’s “resilience beyond COVID revenue challenges,” citing pipeline diversity and cost discipline as stabilizers. Pfizer: Resilience Beyond COVID Revenue Challenges
• Neutral Sentiment: Barchart notes unusual put-option volume but stresses that upgraded guidance undercuts a purely bearish interpretation. Unusual Put Option Activity in Pfizer Stock - Have Investors Turned Bearish?
• Neutral Sentiment: A Sohu report explains Pfizer’s use of a long-strangle options strategy to navigate market volatility, a technical maneuver with limited immediate stock impact. Understanding Pfizer's Long Strangle Options Strategy Amid Market Volatility
• Negative Sentiment: TalkMarkets highlights unusual put activity, raising questions about growing bearish bets even as valuation appears historically cheap. Unusual Put Option Activity In Pfizer Stock - Have Investors Turned Bearish?
• Negative Sentiment: MSN reports a spike in put volume, characterizing the directional flow as bearish and potentially signaling downside pressure. Pfizer put volume heavy and directionally bearish
• Negative Sentiment: MarketBeat notes a 2.2% intraday decline tied to profit-taking after earnings and mixed guidance commentary. Pfizer (NYSE:PFE) Trading Down 2.2% - Here's What Happened
• Negative Sentiment: GeekWire and MSN both report Pfizer cut 100 jobs in the Seattle/Bothell area, reflecting cost-cutting measures that may weigh on sentiment. Pfizer lays off 100 employees in Seattle area